Selected research
Industry Research
Parasitic Diseases Therapeutic Industry Research Report 2026
Market perspective
The global Parasitic Diseases Therapeutic market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Parasitic Diseases Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Parasitic Diseases Therapeutic market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Parasitic Diseases Therapeutic market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Parasitic Diseases Therapeutic include Pfizer, GlaxoSmithKline, Bayer, Sanaria and F. Hoffmann-La Roche, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Parasitic Diseases Therapeutic market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Parasitic Diseases Therapeutic.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Parasitic Diseases Therapeutic Market by Company
Pfizer
GlaxoSmithKline
Bayer
Sanaria
F. Hoffmann-La Roche
Parasitic Diseases Therapeutic Segment by Type
Acaricide
Insect Repellent
Peptides Medicine
Other
Parasitic Diseases Therapeutic Segment by Application
Commercial
Household
Parasitic Diseases Therapeutic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parasitic Diseases Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parasitic Diseases Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parasitic Diseases Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Parasitic Diseases Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Acaricide
- Insect Repellent
- Peptides Medicine
- Other
Applications
- Commercial
- Household
Companies covered
- Pfizer
- GlaxoSmithKline
- Bayer
- Sanaria
- F. Hoffmann-La Roche
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Parasitic Diseases Therapeutic by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Acaricide
- 2.2.3 Insect Repellent
- 2.2.4 Peptides Medicine
- 2.2.5 Other
- 2.3 Parasitic Diseases Therapeutic by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Commercial
- 2.3.3 Household
- 2.4 Assumptions and Limitations
3 Parasitic Diseases Therapeutic Breakdown Data by Type
- 3.1 Global Parasitic Diseases Therapeutic Historic Market Size by Type (2021-2026)
- 3.2 Global Parasitic Diseases Therapeutic Forecasted Market Size by Type (2027-2032)
4 Parasitic Diseases Therapeutic Breakdown Data by Application
- 4.1 Global Parasitic Diseases Therapeutic Historic Market Size by Application (2021-2026)
- 4.2 Global Parasitic Diseases Therapeutic Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Parasitic Diseases Therapeutic Market Perspective (2021-2032)
- 5.2 Global Parasitic Diseases Therapeutic Growth Trends by Region
- 5.2.1 Global Parasitic Diseases Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Parasitic Diseases Therapeutic Historic Market Size by Region (2021-2026)
- 5.2.3 Parasitic Diseases Therapeutic Forecasted Market Size by Region (2027-2032)
- 5.3 Parasitic Diseases Therapeutic Market Dynamics
- 5.3.1 Parasitic Diseases Therapeutic Industry Trends
- 5.3.2 Parasitic Diseases Therapeutic Market Drivers
- 5.3.3 Parasitic Diseases Therapeutic Market Challenges
- 5.3.4 Parasitic Diseases Therapeutic Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Parasitic Diseases Therapeutic Players by Revenue
- 6.1.1 Global Top Parasitic Diseases Therapeutic Players by Revenue (2021-2026)
- 6.1.2 Global Parasitic Diseases Therapeutic Revenue Market Share by Players (2021-2026)
- 6.2 Global Parasitic Diseases Therapeutic Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Parasitic Diseases Therapeutic Head Office and Area Served
- 6.4 Global Parasitic Diseases Therapeutic Players, Product Type & Application
- 6.5 Global Parasitic Diseases Therapeutic Manufacturers Established Date
- 6.6 Global Parasitic Diseases Therapeutic Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Parasitic Diseases Therapeutic Market Size (2021-2032)
- 7.2 North America Parasitic Diseases Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Parasitic Diseases Therapeutic Market Size by Country (2021-2026)
- 7.4 North America Parasitic Diseases Therapeutic Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Parasitic Diseases Therapeutic Market Size (2021-2032)
- 8.2 Europe Parasitic Diseases Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Parasitic Diseases Therapeutic Market Size by Country (2021-2026)
- 8.4 Europe Parasitic Diseases Therapeutic Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Parasitic Diseases Therapeutic Market Size (2021-2032)
- 9.2 Asia-Pacific Parasitic Diseases Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Parasitic Diseases Therapeutic Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Parasitic Diseases Therapeutic Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Parasitic Diseases Therapeutic Market Size (2021-2032)
- 10.2 South America Parasitic Diseases Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Parasitic Diseases Therapeutic Market Size by Country (2021-2026)
- 10.4 South America Parasitic Diseases Therapeutic Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Parasitic Diseases Therapeutic Market Size (2021-2032)
- 11.2 Middle East & Africa Parasitic Diseases Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Parasitic Diseases Therapeutic Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Parasitic Diseases Therapeutic Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Pfizer
- 12.1.1 Pfizer Company Information
- 12.1.2 Pfizer Business Overview
- 12.1.3 Pfizer Revenue in Parasitic Diseases Therapeutic Business (2021-2026)
- 12.1.4 Pfizer Parasitic Diseases Therapeutic Product Portfolio
- 12.1.5 Pfizer Recent Developments
- 12.2 GlaxoSmithKline
- 12.2.1 GlaxoSmithKline Company Information
- 12.2.2 GlaxoSmithKline Business Overview
- 12.2.3 GlaxoSmithKline Revenue in Parasitic Diseases Therapeutic Business (2021-2026)
- 12.2.4 GlaxoSmithKline Parasitic Diseases Therapeutic Product Portfolio
- 12.2.5 GlaxoSmithKline Recent Developments
- 12.3 Bayer
- 12.3.1 Bayer Company Information
- 12.3.2 Bayer Business Overview
- 12.3.3 Bayer Revenue in Parasitic Diseases Therapeutic Business (2021-2026)
- 12.3.4 Bayer Parasitic Diseases Therapeutic Product Portfolio
- 12.3.5 Bayer Recent Developments
- 12.4 Sanaria
- 12.4.1 Sanaria Company Information
- 12.4.2 Sanaria Business Overview
- 12.4.3 Sanaria Revenue in Parasitic Diseases Therapeutic Business (2021-2026)
- 12.4.4 Sanaria Parasitic Diseases Therapeutic Product Portfolio
- 12.4.5 Sanaria Recent Developments
- 12.5 F. Hoffmann-La Roche
- 12.5.1 F. Hoffmann-La Roche Company Information
- 12.5.2 F. Hoffmann-La Roche Business Overview
- 12.5.3 F. Hoffmann-La Roche Revenue in Parasitic Diseases Therapeutic Business (2021-2026)
- 12.5.4 F. Hoffmann-La Roche Parasitic Diseases Therapeutic Product Portfolio
- 12.5.5 F. Hoffmann-La Roche Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst